肥胖现象型和异位性脂质不良症
Hun Jee Choe1, Talal Almas2, Ian J Neeland2,3
1Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, South Korea.
European journal of clinical investigation
|November 21, 2025
概括
肥胖现象,特别是内脏脂肪,驱动动动脉动性脂质障碍和心血管疾病的风险. 针对性治疗和精准医学对于管理心血管-脏-代谢综合征中的这些相互关联的疾病至关重要.
科学领域:
- 心血管医学 心血管医学
- 代谢综合征是代谢综合征的一种.
- 肥胖问题研究研究
背景情况:
- 肥胖和动脉质性脂质障碍是动脉质性心血管疾病 (ASCVD) 和心血管--代谢 (CKM) 综合征的关键驱动因素.
- 肥胖的异质性,特别是内脏和宫外脂肪,决定了失脂症的表型,如过高甘油三和改变的脂蛋白水平.
研究的目的:
- 审查证据,将肥胖现象与失脂症和心血管结果联系起来.
- 评估与肥胖相关的脂质异常的干预措施.
主要方法:
- 审查流行病学研究,成像,遗传数据和临床试验.
- 评估生活方式,药理和手术策略.
主要成果:
- 与单独的BMI相比,内脏和宫外脂肪积累是不良脂质配置,胰岛素抵抗和心血管事件的更强有力的预测因素.
- 生活方式干预改善脂质代谢独立于减肥;新型药物治疗和减肥手术提供显著的代谢益处.
- 异位性脂质失调症导致剩余的ASCVD风险,即使低密度脂蛋白胆固醇降低.
结论:
- 在CKM框架内,原性脂质障碍症是高风险肥胖现象的特征,是ASCVD的主要贡献者.
- 精准医学,包括肥胖表型和向疗法,对于减轻脱脂症及其心血管后果的负担至关重要.
相关概念视频
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Cholesterol: Significance and Regulation
1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.2K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
228
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
228
Overview of Lipid Metabolism
4.7K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.7K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
162
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
162
Drug Dosing: Obese Patients
204
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
204


